Chai Discovery's $130M Series B and the open-source Chai-1 protein-structure model put the category back in conversation against AlphaFold 3 and Isomorphic Labs. Recursion and Tempus operate the largest phenomics and clinical-genomics datasets in the public-comparable set, while Insilico Medicine pushed its first generative-AI-designed molecule INS018_055 into Phase II for IPF. Owkin partners with hospitals on federated learning, EvolutionaryScale shipped ESM3 as a frontier protein language model, and Xaira Therapeutics launched in 2024 with one of the largest seed rounds in biotech history. Atomwise, Cradle, Latent Labs, and Iambic round out the computational-chemistry layer.
CATEGORY
Best Drug Discovery AI Tools
52 tools compared · 2026
Generative chemistry, protein language models, and AI scientists targeting the trillion-dollar pharma R&D bottleneck
52 drug discovery startups tracked, with the largest concentration in US. Total tracked funding: $9.2B.
Tracked
52
Total Raised
$9.2B
Countries
7
Active Deals
0
1 
Isomorphic Labs — $2.7B 2 
Treeline Biosciences Stamford, US $1.1B 3 
Generate:Biomedicines Somerville, United States $700M 4 
Recursion Salt Lake City, US $500M 5 
Genesis Molecular AI Burlingame, US $280M 6 
Terray Therapeutics Monrovia, US $180M 7 
Basecamp Research London, GB $85M 8 
Insilico Medicine US $510M 9 
Pathos AI — $467M 10 
Owkin FR $354M 11 
Genesis Therapeutics — $344M 12 
Nabla Bio Boston, US $37M
Funding by year — Drug Discovery
2019 → 2026Market overview
Key trends 2026
- Foundation-model biology arrives. Chai-1, ESM3, and AlphaFold 3 reset the structure-prediction baseline for in silico screening.
- Phase II readouts begin. Insilico's INS018_055 IPF program gives the first generative-AI-discovered drug a real clinical signal.
- Federated data beats centralized scraping. Owkin's hospital network model sidesteps the patient-data licensing wall that blocks others.
Benchmarks vs global
First AI-designed drug in Phase II
INS018_055 (Insilico)
vs zero pre-2023 ↑
Largest tracked round
$130M (Chai Series B)
vs Xaira's $1B 2024 launch ↑
Hit-rate uplift, AI-led campaigns
4-10x (Enveda claim)
vs traditional HTS baseline ↑
Top countries
By startup countStage breakdown
Latest round typeTop investors backing Drug Discovery
See all →Lux Capital
6 deals
General Catalyst
6 deals
GV (Google Ventures)
6 deals
SP
Sofinnova Partners
5 deals
AV
ARCH Venture Partners
5 deals
MC
Mubadala Capital
3 deals
F
F-Prime
3 deals
B
Bpifrance
3 deals
BL
Bpifrance Large Venture
3 deals
CI
Cathay Innovation
3 deals
Menlo Ventures
3 deals
Spark Capital
3 deals
FAQ
Frequently asked
Which AI drug-discovery startup has raised the most?
Among our tracked startups Chai Discovery leads at $130M Series B. Public peers Recursion and Tempus have raised more historically (Recursion $400M+ pre-IPO, Tempus IPO 2024) but trade as listed companies rather than VC-staged startups.
Has any AI-designed drug reached clinical trials?
Yes. Insilico Medicine's INS018_055 for idiopathic pulmonary fibrosis advanced into Phase II — the first molecule with both target identified and structure designed by generative AI to reach that stage. Several Recursion and Iambic candidates are in Phase I.
What does Chai-1 give researchers that AlphaFold 3 doesn't?
Chai-1 ships with weights downloadable for non-commercial research and matches AlphaFold 3 on ligand and antibody benchmarks. AlphaFold 3 is gated behind Isomorphic's web server with usage caps, which limits high-throughput in-silico screening pipelines.
Recent rounds in Drug Discovery
All rounds →| Date | Startup | Round | Amount |
|---|---|---|---|
| Jun 2026 | Apoha | Series A | $36M |
| May 2026 | Perceptic | Seed | $12M |
| May 2026 | Genesis Therapeutics | Strategic Equity Investment | $40M |
| May 2026 | Imperagen | Seed | $6.7M |
| May 2026 | Isomorphic Labs | Series B | $2.1B |
| Jan 2026 | Enjamb Labs | Seed | $500K |
| Dec 2025 | Chai Discovery | Series B | $130M |
| Dec 2025 | Paradigm Health | Series B | $78M |
All Drug Discovery startups
Page 3Imperagen
Closed-loop, AI-guided enzyme engineering for improved and production-ready enzyme designs.
Raised
$6.7M
Stage
Seed
Biomatter
Generative AI for protein and enzyme design across industries
Raised
$7M
Stage
Seed
Bindwell
Raised
$6M
Stage
Seed
Profluent
Frontier AI models for programmable biology and protein design
Raised
$150M
Stage
S-B